Kamada (KMDA) Share-based Compensation (2012 - 2026)
Kamada (KMDA) posted quarterly Share-based Compensation of $800000.0 for Q1 2026, up 357.14% year-on-year from $175000.0 in Q1 2025, and up 127.92% on a QoQ basis from $351000.0 in Q4 2025.
Kamada (KMDA) Share-based Compensation (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Share-based Compensation for 15 consecutive years, with $800000.0 the latest figure, recorded in Q1 2026.
- Quarterly Share-based Compensation rose 357.14% year-over-year to $800000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 75.87% YoY) and the FY2025 annual result came in at $845000.0, down 74.42% from the prior year.
- Share-based Compensation grew to $800000.0 in Q1 2026 per KMDA's latest filing, from $351000.0 in the prior quarter.
- Over the last five years, Share-based Compensation for KMDA reached as high as $2.7 million in Q4 2023 and fell as low as $366.0 in Q3 2022.
- A 5-year average of $362693.0 and a median of $214000.0 in 2023 frame the typical range for Share-based Compensation.
- The largest YoY upside for Share-based Compensation was 85145.9% in 2023 against a maximum downside of 99.78% in 2023.
- Year by year, Share-based Compensation stood at $25000.0 in 2022, then jumped by 10564.0% to $2.7 million in 2023, then plunged by 94.71% to $141000.0 in 2024, then surged by 148.94% to $351000.0 in 2025, then jumped by 127.92% to $800000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $800000.0, $351000.0, and $117000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Sep 30, 2025 | 117,000.00 |
| Sep 30, 2025 | 117,000.00 |
| Jun 30, 2025 | 95,000.00 |
| Jun 30, 2025 | 95,000.00 |
| Mar 31, 2025 | 175,000.00 |
| Mar 31, 2025 | 175,000.00 |
| Dec 31, 2024 | 141,000.00 |
| Dec 31, 2024 | 141,000.00 |
| Sep 30, 2024 | 224,000.00 |
| Sep 30, 2024 | 224,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Dec 31, 2023 | 2.67 Mn |
| Dec 31, 2023 | 2.67 Mn |